Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information...
Cheers
Ulf
9.27.2011
AMNOG and its implications in Germany - Webinar
Dear All,
please find below an announcement for a webinar organized by Kakushin group about the changes introduced by the new drug law in Germany and its potential implications. I will give an overview from a pricing perspective.
No comments:
Post a Comment